SciSparc Ltd.
SPRC
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement wā¦ read more
Healthcare
Biotechnology
2 years
USD
Price
per share adjusted in USD$4.54
Price+0.67%
$0.03
1Y
Price
Market Cap
$2.427m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$4.185m
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$11.406m
-
1y CAGR-
3y CAGR-
5y CAGREPS
-$81.55
-
1y CAGR-
3y CAGR-
5y CAGRBook Value
$8.939m
$10.347m
Assets$1.408m
Liabilities$46k
DebtDebt to Assets
0.4%
-
Debt to EBITDAFree Cash Flow
-$10.991m
-
1y CAGR-
3y CAGR-
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company